Archives
Tag Archives for: "ISA"
Tag Archives for: "ISA"
Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B infection
Oegstgeest, The Netherlands, 31 August 2023 – ISA is pleased to announce that the first patient has been dosed in the HEB-PEP study. This first-in-human (FIH) phase 1 study investigates the use of ISA104, a novel treatment aimed to establish functional cure in Chronic Hepatitis B patients. Dosing took place at the Liver Unit of the Erasmus Medical Center in Rotterdam, the sponsor of this dose escalation study.
The HEB-PEP study will investigate the safety, tolerability and efficacy of different doses of ISA104 in
Read more »The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy fieldSecond SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting
Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro J. Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). This Award recognizes individuals who made immeasurable contributions to the Journal for Immunotherapy of Cancer (JITC) – the official journal of the SITC. The award will be presented at the SITC’s 37th
Read more »Oegstgeest, May 3rd, 2021 – ISA is happy to announce it has moved into its new location in the Biopartner 5 building, situated in the western part of the Leiden/Oegstgeest BioScience park.
Our new address is:De Limes 72342 DH OegstgeestThe Netherlands
The novel ISA facilities constitute a doubling in size of office and lab space, compared to its former location, with possibilities to further expand. Over the past period ISA has grown substanially and will continue to do so in the coming period. This new location is perfectly suited to accommodate this growth.
The Biopartner 5 building is designed with emphasis on sustainability:
Read more »Our CEO Gerben Moolhuizen will present on Thursday, June 25 at the Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.
Date: Thursday, June 25, 2020Time: 3:40pm CET / 9:40am EDT.Access to webcast: https://www.webcaster4.com/Webcast/Page/2408/35366
You may access the stream 15 minutes in advance and a replay of the webcast will be available for 60 days.
Read more »Leiden, The Netherlands, June 17, 2020, — ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, today announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo® (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals.
The new oropharyngeal cancer trial is
the third trial planned under the clinical collaboration between ISA Pharmaceuticals
and Regeneron. ISA101b, an immunotherapy targeting human papillomavirus type 16
(HPV16), is currently in a Phase 2 clinical trial for first- and second-line
HPV16-positive head-and-neck cancer in combination with
The platform for the medical research community MedNous wrote an article about our CervISA study:
Synthetic long peptides deliver response
A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy.
Sunday 22 March 2020A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy. The Phase 2 trial showed that the vaccine and carboplatin/paclitaxel chemotherapy were associated with prolonged survival.
The study was led by Cornelis Melief, chief scientific officer of ISA Pharmaceuticals
Read more »Financing
to boost late-stage development of novel therapy to treat life-threatening, virus-induced
cancersLoan supported
by the “InnovFin
–
EU-finance for innovators”
programme
The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).
Persistent
HPV16 infection can cause cervical, head & neck and anogenital cancers.
These cancers can be severe and life-threatening, with low overall survival
rates of advanced stages. Cervical cancer is the 2nd most common
cancer in women aged 15 to 44 years in Europe, with HPV16 causing over 35,000
new cases and 15,000 deaths each year. The